Case Report
CD7-Positive Diffuse Large B-Cell Lymphoma Presenting as an Intranasal Tumor
Table 1
Clinical characteristics of CD7-positive B-cell lymphoma.
| | Case No. | Age | Sex | Histology | Cell of origin | Main site(s) of involvement | Stage | Extranodal involvement | Treatment | Response | Status | Follow-up (months) | Detection method | References |
| | Case 1 | 54 | F | DLBCL | Non-GC | Inguinal LN | IIA | − | R-CHOP | CR | Alive, CR | NA | FCM, IHC | Sangle et al. | | Case 2 | 66 | M | DLBCL | NA | Thoracic cavity | IA | + | CHOP + RT | PR | Died of disease | NA | FCM, IHC | Tomita et al. | | Case 3 | 47 | M | Non-Hodgkin lymphoma | NA | Intra-abdominal mass | IVA | + | High dose CHOP | PD | Died of disease | 5 | FCM | Takahashi et al. | | Case 4 | 64 | M | DLBCL | GC | Cecum | IIA | + | Surgery + R-CHOP | CR | Alive, CR | 68 | IHC | Tsuyama et al. | | Case 5 | 66 | F | DLBCL | Non-GC | Axillary LN | IVB | + | R-CHOP + RT | PD | Died of disease, refractory | 24 | FCM, IHC | Tsuyama et al. | | Case 6 | 62 | F | DLBCL | GC | Nasal cavity | IIA | + | R-CHOP | PR | Alive with disease, relapse | 34 | FCM, IHC | Tsuyama et al. | | Case 7 | 82 | M | DLBCL | Non-GC | Nasal cavity | IA | + | R-CHOP | CR | Alive, CR | 45 | FCM, IHC | Tsuyama et al. | | Case 8 | 64 | M | DLBCL | Non-GC | Orbit | IB | + | R-CHOP | PD | Died of disease | 2 | FCM, IHC | Tsuyama et al. | | Case 9 | 81 | M | DLBCL | Non-GC | Soft tissue of leg | IVA | + | R-CHOP | CR | Died of disease, relapse | 40 | FCM, IHC | Tsuyama et al. | | Case 10 | 55 | M | DLBCL | Non-GC | Cervical LN | IVA | + | R-CHOP | CR | Died of disease, relapse | 12 | FCM, IHC | Tsuyama et al. | | Case 11 | 65 | M | DLBCL | Non-GC | Prostate | IVA | + | R-CHOP | CR | Alive, CR | 49 | FCM, IHC | Tsuyama et al. | | Case 12 | 74 | M | DLBCL | Non-GC | Nasal cavity | IA | + | R-CHOP + RT | CR | Alive, CR | 18 | FCM | Our case |
|
|
M, male; F, female; DLBCL, diffuse large B-cell lymphoma; GC, germinal centre; LN, lymph node; CR, complete response; PR, partial response; PD, progressive disease; NA, not available; FCM, flow cytometry; IHC, immunohistochemistry.
|
